Ultragenyx Pharmaceutical annual ebitda
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ultragenyx Pharmaceutical EBITDA Growth & History (RARE)
Ultragenyx Pharmaceutical's calculated EBITDA was −$500.0M for fiscal 2025.
View full Ultragenyx Pharmaceutical company overviewUltragenyx Pharmaceutical annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$500.0M | $0 | — |
| 2024 | 2024-12-31 | −$500.0M | $43.0M | — |
| 2023 | 2023-12-31 | −$543.0M | $87.7M | — |
| 2022 | 2022-12-31 | −$630.7M | −$262.2M | — |
| 2021 | 2021-12-31 | −$368.5M | −$50.6M | — |
| 2020 | 2020-12-31 | −$317.9M | $97.8M | — |
| 2019 | 2019-12-31 | −$415.6M | −$63.8M | — |
| 2018 | 2018-12-31 | −$351.8M | −$28.7M | — |
| 2017 | 2017-12-31 | −$323.1M | −$78.5M | — |
| 2016 | 2016-12-31 | −$244.6M | −$98.2M | — |
| 2015 | 2015-12-31 | −$146.4M | −$90.3M | — |
| 2014 | 2014-12-31 | −$56.1M | −$24.3M | — |
| 2013 | 2013-12-31 | −$31.8M | −$16.2M | — |
| 2012 | 2012-12-31 | −$15.7M | — | — |
Ultragenyx Pharmaceutical quarterly ebitda
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$67.0M | $32.0M | — |
| Q1 2026 | 2026-03-31 | −$161.0M | −$27.0M | — |
| Q4 2025 | 2025-12-31 | −$104.3M | $8.4M | — |
| Q3 2025 | 2025-09-30 | −$162.7M | −$39.4M | — |
| Q2 2025 | 2025-06-30 | −$99.0M | $8.5M | — |
| Q1 2025 | 2025-03-31 | −$134.0M | $22.5M | — |
| Q4 2024 | 2024-12-31 | −$112.8M | $860,000 | — |
| Q3 2024 | 2024-09-30 | −$123.2M | $14.7M | — |
| Q2 2024 | 2024-06-30 | −$107.5M | $35.1M | — |
| Q1 2024 | 2024-03-31 | −$156.5M | −$7.6M | — |
| Q4 2023 | 2023-12-31 | −$113.6M | $27.0M | — |
| Q3 2023 | 2023-09-30 | −$137.9M | $82.5M | — |
| Q2 2023 | 2023-06-30 | −$142.6M | −$5.5M | — |
| Q1 2023 | 2023-03-31 | −$148.9M | −$16.3M | — |
| Q4 2022 | 2022-12-31 | −$140.7M | −$41.6M | — |
| Q3 2022 | 2022-09-30 | −$220.4M | −$133.8M | — |
| Q2 2022 | 2022-06-30 | −$137.1M | −$57.5M | — |
| Q1 2022 | 2022-03-31 | −$132.5M | −$29.3M | — |
| Q4 2021 | 2021-12-31 | −$99.0M | −$6.1M | — |
| Q3 2021 | 2021-09-30 | −$86.6M | −$39.4M | — |
| Q2 2021 | 2021-06-30 | −$79.7M | −$19.8M | — |
| Q1 2021 | 2021-03-31 | −$103.2M | $14.6M | — |
| Q4 2020 | 2020-12-31 | −$92.9M | −$665,000 | — |
| Q3 2020 | 2020-09-30 | −$47.2M | $68.7M | — |
| Q2 2020 | 2020-06-30 | −$59.9M | $50.5M | — |
| Q1 2020 | 2020-03-31 | −$117.8M | −$20.7M | — |
| Q4 2019 | 2019-12-31 | −$92.3M | −$4.9M | — |
| Q3 2019 | 2019-09-30 | −$115.9M | −$30.6M | — |
| Q2 2019 | 2019-06-30 | −$110.4M | −$21.5M | — |
| Q1 2019 | 2019-03-31 | −$97.1M | −$6.8M | — |
| Q4 2018 | 2018-12-31 | −$87.4M | $6.9M | — |
| Q3 2018 | 2018-09-30 | −$85.3M | −$2.7M | — |
| Q2 2018 | 2018-06-30 | −$88.8M | −$11.4M | — |
| Q1 2018 | 2018-03-31 | −$90.3M | −$21.5M | — |
| Q4 2017 | 2017-12-31 | −$94.3M | −$24.9M | — |
| Q3 2017 | 2017-09-30 | −$82.6M | −$17.9M | — |
| Q2 2017 | 2017-06-30 | −$77.4M | −$20.0M | — |
| Q1 2017 | 2017-03-31 | −$68.8M | −$15.7M | — |
| Q4 2016 | 2016-12-31 | −$69.4M | −$13.7M | — |
| Q3 2016 | 2016-09-30 | −$64.8M | −$25.3M | — |
| Q2 2016 | 2016-06-30 | −$57.4M | −$27.5M | — |
| Q1 2016 | 2016-03-31 | −$53.1M | −$31.8M | — |
| Q4 2015 | 2015-12-31 | −$55.7M | −$38.9M | — |
| Q3 2015 | 2015-09-30 | −$39.5M | −$23.9M | — |
| Q2 2015 | 2015-06-30 | −$29.9M | −$16.4M | — |
| Q1 2015 | 2015-03-31 | −$21.3M | −$11.1M | — |
| Q4 2014 | 2014-12-31 | −$16.7M | −$7.3M | — |
| Q3 2014 | 2014-09-30 | −$15.6M | −$8.0M | — |
| Q2 2014 | 2014-06-30 | −$13.5M | −$5.4M | — |
| Q1 2014 | 2014-03-31 | −$10.2M | −$3.6M | — |
| Q4 2013 | 2013-12-31 | −$9.4M | — | — |
| Q3 2013 | 2013-09-30 | −$7.7M | — | — |
| Q2 2013 | 2013-06-30 | −$8.1M | — | — |
| Q1 2013 | 2013-03-31 | −$6.6M | — | — |
Ultragenyx Pharmaceutical ebitda trends
Over the last five fiscal years, Ultragenyx Pharmaceutical's ebitda decreased from −$317.9M to −$500.0M, a change of −$182.1M. The latest reported quarter, Q2 2026, shows −$67.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ultragenyx Pharmaceutical source filings ↗Community posts
Ultragenyx wins FDA approval for its Sanfilippo gene therapy
Ultragenyx ($RARE) received standard FDA approval for FAYUVI, the first approved treatment for Sanfilippo syndrome Type A. The single-infusion gene therapy treats neurological manifestations in pediatric patients with preserved neurodevelop ...
